BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces that the US Patent and Trademark Office (USPTO) has granted Implanet a patent for the JAZZ® technological platform in the United States.
The JAZZ technological platform’s intellectual protection now covers the braided implant and its tensioning system, the principal element of its instrumentation. Implanet now possesses intellectual property architecture covering the specificities of its JAZZ® platform in the countries defined as priority markets during the Company’s IPO, i.e. the United States, Europe, China, Japan, Australia and South Africa. Implanet is now the only spine surgery player, apart from Zimmer Spine, to have patents for a spinal fixation technical solution enabling the braid’s tension and the implant’s position on the rod to be locked with a single screw.
Régis Le Couedic, Implanet’s Product Development & Manufacturing Director, says: “Being granted this patent in the world’s most advanced medical market represents major recognition by the authorities of the pre-eminence and innovative nature of our spine implant technology. This patent is a guarantee of JAZZ’s future in the United States, where surgeons demand increasingly innovative medical technologies. Our band implant and its tensioning instrument are now protected in our priority markets, and we will continue to extend our field of protection to other innovations currently in late-stage development.”
Ludovic Lastennet, CEO of Implanet, adds: “Obtaining this patent is a major value-creation milestone for Implanet. This protection creates a solid barrier to potential competitors in an American market that places a strong emphasis on intellectual property rights. Thanks to this protection, we have total confidence in our continued acceleration in the United States.”
Next financial press release: results for the 1st half of 2016, on September 23, 2016
Upcoming congresses and conferences:
SRS in Prague,
September 21 to 24, 2016
ICCC in São Paulo, September 30 to October
1, 2016
EUROSPINE in Berlin, October 6 to 8, 2016
NASS in
Boston, October 26 to 28, 2016
SOFCOT in Paris, November 8 to 11,
2016
Reminder of recent press releases:
Green light for a new
implant: JAZZ Lock®, April 2016
Q1 2016 revenues: Strong increase
in U.S. JAZZ sales: +106%, April 2016
Launch of the new JAZZ Claw®
implant, May 2016
Q2 2016 record revenue of €2.1 million with Spine
sales growing by +68%, July 2016
About IMPLANET
Founded in 2007, IMPLANET is a medical
technology company that manufactures high-quality implants for
orthopedic surgery. Its flagship product, the JAZZ latest-generation
implant, aims to treat spinal pathologies requiring vertebral fusion
surgery. Protected by four families of international patents, JAZZ has
obtained 510(k) regulatory clearance from the Food and Drug
Administration (FDA) in the United States and the CE mark. IMPLANET
employs 48 staff and recorded 2015 sales of €6.7 million. For further
information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in
Boston in 2013.
IMPLANET is listed on Compartment C of the
Euronext™ regulated market in Paris.